Clinicopathological and molecular features of HR + /HER2 - breast cancer patients with distinct endocrine resistance patterns

Researchers explored molecular features and therapeutic targets for patients with HR+ HER2- breast cancer who experienced disease recurrence. They found that patients with different relapse patterns presented with unique molecular features in their primary tumors, which can potentially guide targeted therapies.